Recombinant tumor necrosis factor α (TNFα) is also licensed by several regulatory agencies worldwide (but not by the US FDA), for the treatment of limb-threatening soft tissue sarcoma and melanoma [290-292]. Here, TNF is linked to soft tissue sarcoma.